Quetiapine Fumarate Tablets

Quetiapine fumarate tablets,

common noun

Quetiapine Fumarate Tablets

,

store

Siruikang

,

English name

Quetiapine

3 aminopropionitrilefumarate

medicinal tablet

,

Registration authentication number

H20030 192

,

Production enterprise

AstraZeneca

Britain

limited

,

standard

0.2gx20 tablets/box

,

indicate

Can be used for treating schizophrenia.

,

dosage

It should be given twice a day, before and after meals.

Adults: The total daily dose for the first four days of treatment was 50 mg (day one), 100 mg (day two), 200 mg (day three) and 300 mg (day four) respectively. After the fourth day, the near dose gradually increased to the effective dose range, generally 300-450mg/ day. The dosage can be adjusted between 150-750mg/ day according to the patient's clinical response and tolerance.

,

Contraindications

Patients who are allergic to any component of this product are prohibited.

,

Matters needing attention

cardiovascular disease

"Siruikang" may cause orthostatic hypotension, especially in the initial administration period; The above phenomenon is more common in elderly patients than in young patients. In clinical trials, quetiapine has nothing to do with prolonged QTc interval. However, like other antipsychotics, quetiapine combined with other drugs known to prolong QTc interval is cautious, especially in the elderly.

Patients with known cardiovascular and cerebrovascular diseases or other hypotensive tendencies should be cautious in using Sirikang.

shake

In clinical controlled trials, there is no difference in the incidence of convulsions between patients taking "Xerox" and patients taking placebo. As with other antipsychotics, attention should be paid to the treatment of patients with a history of convulsions.

Nerve block malignant syndrome

The treatment of antipsychotics will be accompanied by malignant syndrome of antipsychotics. Clinical manifestations include high fever, mental state change, muscular rigidity, autonomic nerve dysfunction and increased creatine phosphokinase activity. If this happens, you should stop using Sirikang and give appropriate treatment.

Delayed dyskinesia

Like other antipsychotics, long-term use of "Siruikang" may also lead to tardive dyskinesia. If there are signs and symptoms of tardive dyskinesia, we should consider reducing the dose of Sirikan or stopping using it.

,

Medication for pregnant and lactating women

The efficacy and safety of human pregnancy have not been confirmed (see the reproductive research section of preclinical case data for animal reproductive toxicity data). Therefore, Siruikang can only be used for pregnant patients if the benefits outweigh the potential risks.

,